Preoperative Tyrosine Kinase Inhibition as an Adjunct to Debulking Nephrectomy
Authors:
- Eric WallenEWEric Wallen
- Raj S. PruthiRPRaj S. Pruthi
- Benjamin F. CalvoBCBenjamin F. Calvo
- Paul A. GodleyPGPaul A. Godley
- W. Kimryn RathmellWRW. Kimryn Rathmell
Abstract
No abstract availableKeywords
Funding Information
- Doris Duke Charitable Foundation
This publication has 16 references indexed in Scilit:
- Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)British Journal of Cancer, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized TrialJournal of Clinical Oncology, 2003
- The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinomaUrologic Clinics of North America, 2003
- The Timing of Immunotherapy and Nephrectomy in Multimodality Treatment of Metastatic Renal Cell CarcinomaTechnology in Cancer Research & Treatment, 2003
- BAY 43-9006: Preclinical DataCurrent Pharmaceutical Design, 2002
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Nephrectomy and Interleukin-2 for Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2001
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 2001
- Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized StudyJournal of Clinical Oncology, 2001